查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094127

快速微生物檢測市場－2026-2032年全球市場預測

Rapid Microbiology Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，快速微生物檢測市場將成長至 92.1 億美元，複合年成長率為 7.79%。

主要市場統計數據
基準年 2025 54.5億美元
預計年份：2026年 58.6億美元
預測年份 2032 92.1億美元
複合年成長率 (%) 7.79%

快速微生物檢測正在重塑醫療保健專業人員、製藥公司、食品飲料製造商、環境檢測實驗室和公共衛生機構檢測、識別和應對微生物污染和感染疾病的方式。與傳統的依賴培養的方法（可能需要數天才能觀察到可見的生長或進行確認分析）不同，快速微生物檢測利用核酸擴增、聚合酵素鏈鎖反應(PCR)、次世代定序、基質輔助雷射脫附游離飛行質譜 (MALDI-TOF)、免疫檢測、流式細胞術、ATP生物發光、自動化時間質譜法 (MALDI-TOF)、免疫分析、流式細胞技術、ATP分子冷光發光、自動化培養系統和生物感測器等技術，加速微生物的檢測和表徵。

快速微生物檢測的策略價值源自於許多需求，例如加速臨床決策、合理使用抗生素、控制污染、提高產品放行效率、預防感染、因應集體爆發。在臨床環境中，及時識別病原體有助於進行標靶抗生素治療，從而減少對頻譜抗生素的依賴。在製藥和生物技術生產中，快速微生物檢測支援品質源自於設計 (QbD) 原則，同時加強無菌保證、微生物附著量監測和環境監測計畫。在食品安全領域，快速檢測能夠提高整個生產和分銷網路中的危害檢測能力，幫助企業應對沙門氏菌、單核細胞增生李斯特菌、大腸桿菌和曲狀桿菌等病原體。

監管要求、醫療保健數位化、檢查室自動化以及日益加重的全球感染疾病負擔，正推動快速微生物檢測的重要性日益凸顯。該領域正逐漸從孤立的檢查室工作流程轉向整合的診斷生態系統，其中樣本製備、檢測、分析、報告和監測均透過可互通的數位平台進行協調。

快速微生物檢測領域的變革性變化

隨著檢查室從以人工培養為中心的傳統工作流程轉向自動化、分子生物學和數位化驅動的檢測模式，快速微生物檢測領域正在經歷一場變革。臨床上對當日或近即時病原體檢測的需求、受監管生產場所日益嚴格的污染控制要求以及對強力的公共衛生監測的日益重視，都在加速這一轉變。

人工智慧對快速微生物檢測的累積影響

人工智慧正透過提升模式識別、工作流程效率、品管和決策支援能力，對快速微生物檢測產生累積影響。在需要快速、一致地解讀大量影像、頻譜、基因組序列、抗生素敏感性數據和檢查室元資料的情況下，這種影響尤其顯著。

快速微生物檢測的關鍵區域見解

在亞太地區，由於醫療基礎設施的不斷完善、感染疾病監測能力的提升、藥品生產的成長以及食品安全監管的加強，快速微生物檢測正蓬勃發展。中國、印度、日本、韓國、澳洲和東南亞國協正在推動檢查室現代化、分子診斷以及對公共衛生檢測網路的投資。該地區人口密度高、跨境人口流動頻繁以及疾病負擔多樣，進一步凸顯了快速病原體檢測和抗菌素抗藥性監測的迫切需求。

快速微生物檢測的關鍵群體特異性見解

在北約成員國，快速微生物檢測不僅對醫療保健和公共衛生系統至關重要，而且對生物防禦、保護軍人健康以及緊急準備等優先事項也至關重要。快速病原體偵測、環境監測和現場部署的偵測平台有助於應對生物威脅、控制疫情爆發，並保障民用和國防醫療保健環境的持續運作。

各國對快速微生物檢測的重點見解

美國憑藉其先進的醫院網路、合理使用抗生素的努力、公共衛生監測項目以及對製藥和食品生產行業的嚴格要求，在快速微生物檢測的推廣應用方面發揮著主導作用。中國正透過醫院現代化、分子診斷的普及、感染疾病監測以及對藥品生產品質要求的提高，迅速提升其微生物檢測能力。德國的優勢在於高品質的臨床檢驗醫學、藥品生產和工業微生物學，而日本則兼具先進的檢查室自動化、高標準的醫療水準和強大的品管系統。

為行業領導者提供的實用建議

產業領導者應優先考慮符合臨床、監管、營運和品質目標的、經過檢驗的快速微生物檢測策略。技術選擇不僅應基於速度，還應考慮整體情況，包括預期用途、目標微生物範圍、檢測限、結果報告時間、工作流程相容性、檢體類型相容性、品管要求以及實施準備情況。

調查方法

本執行摘要採用系統性的調查方法編寫而成，該方法著重於對快速微生物檢測現狀進行檢驗和證據的解讀。該調查方法結合了二手研究、法規審查、技術評估和定性分析，旨在識別關鍵趨勢、區域趨勢、應用領域和推廣促進因素，而不依賴市場規模、市場佔有率或預測數據。

結論

快速微生物檢測正日益成為加速診斷速度、加強感染控制、保障食品藥物生產安全、強化公共衛生監測的關鍵功能。該領域正從單純提高微生物檢測速度發展到整合自動化、分子級精度、數位化連接和先進分析能力的綜合系統。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 快速微生物檢測市場：依產品/服務分類

  • 消耗品
    • 培養基
    • 試劑和試劑盒
    • 測試條
  • 裝置
    • 自動化微生物鑑定系統
    • 流式細胞技術系統
    • 微生物檢測系統
    • 樣品製備裝置
    • 光譜/光學設備
  • 軟體
    • 設備控制軟體
    • 檢查資訊系統
    • 決策支援和結果解釋
  • 服務
    • 快速微生物檢測與鑑定
    • 安裝
    • 維護和服務合約

第8章 快速微生物檢測市場：依檢測方法分類

  • 基於培養法的快速微生物檢測
    • ATP生物發光
    • 電阻和電導
    • 二氧化碳和代謝監測
  • 基於存活率的快速微生物檢測
    • 直接螢光濾波（DEFT）
    • 流式細胞技術（螢光法）
  • 基於核酸的快速微生物檢測
    • 聚合酵素鏈鎖反應（PCR）
    • 分子分型
  • 基於細胞成分的快速微生物檢測

第9章 快速微生物檢測市場：依樣本類型分類

  • 人類生物檢體
    • 血液和血液培養
    • 呼吸道檢體
    • 糞便和腸道檢體
    • 尿
  • 藥品樣品
  • 食品和飲料樣品
  • 環境樣品

第10章 快速微生物檢測市場：依應用領域分類

  • 臨床疾病診斷
  • 環境和水質檢測
  • 工業檢驗
    • 化妝品和個人保健產品測試
    • 食品和飲料檢查
  • 製藥和生物製藥生產
  • 研究與學術

第11章 快速微生物檢測市場：依最終用戶分類

  • 外包服務供應商
  • 食品和飲料公司
  • 檢測機構和醫院
  • 製藥和生物技術公司
  • 環境和工業組織

第12章 快速微生物檢測市場：依目標病原體分類

  • 細菌
  • 真菌
  • 病毒

第13章 快速微生物檢測市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 快速微生物檢測市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第15章 快速微生物檢測市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 義大利
  • 巴西
  • 墨西哥
  • 澳洲
  • 俄羅斯
  • 韓國
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • BioMerieux SA
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Abbott Laboratories
  • Merck KGaA
  • Charles River Laboratories International, Inc.
  • Bruker Corporation
  • Sartorius AG
  • Bio-Rad Laboratories, Inc.
  • NEOGEN Corporation
  • Quidel Corporation
  • QIAGEN NV
  • Rapid Micro Biosystems, Inc.
  • Hygiena LLC
  • Avantor, Inc.
  • BTNX Inc.
  • Colifast AS
  • Don Whitley Scientific Limited
  • Eurofins Scientific SE
  • Gradientech AB
  • Guangdong Huankai Microbial Sci. & Tech. Co., Ltd.
  • PerkinElmer, Inc.
  • R-Biopharm AG
  • Rqmicro AG
  • Serosep Ltd.
  • SGS SA
Product Code: MRR-5012464363FE

The Rapid Microbiology Testing Market is projected to grow by USD 9.21 billion at a CAGR of 7.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.45 billion
Estimated Year [2026] USD 5.86 billion
Forecast Year [2032] USD 9.21 billion
CAGR (%) 7.79%

Rapid microbiology testing is reshaping how healthcare providers, pharmaceutical manufacturers, food and beverage producers, environmental laboratories, and public health agencies detect, identify, and respond to microbial contamination and infection. Unlike conventional culture-dependent methods that may require days for visible growth and confirmatory analysis, rapid microbiology testing uses technologies such as nucleic acid amplification, polymerase chain reaction, next-generation sequencing, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, immunoassays, flow cytometry, ATP bioluminescence, automated culture systems, and biosensors to accelerate microbial detection and characterization.

The strategic value of rapid microbiology testing is driven by the need for faster clinical decision-making, antimicrobial stewardship, contamination control, product release efficiency, infection prevention, and outbreak response. In clinical settings, timely pathogen identification supports targeted antimicrobial therapy and reduces reliance on broad-spectrum treatment. In pharmaceutical and biotechnology manufacturing, rapid microbial methods help strengthen sterility assurance, bioburden monitoring, and environmental monitoring programs while supporting quality-by-design principles. In food safety, rapid testing improves hazard detection across production and distribution networks, helping organizations respond to pathogens such as Salmonella, Listeria monocytogenes, Escherichia coli, and Campylobacter.

Regulatory expectations, healthcare digitization, laboratory automation, and the rising global burden of infectious diseases continue to elevate the importance of rapid microbiology testing. The field is increasingly moving from isolated laboratory workflows toward integrated diagnostic ecosystems where sample preparation, detection, analysis, reporting, and surveillance are connected through interoperable digital platforms.

Transformative Shifts in the Rapid Microbiology Testing Landscape

The rapid microbiology testing landscape is undergoing transformative change as laboratories shift from manual, culture-centric workflows toward automated, molecular, and digitally enabled testing models. This transition is being accelerated by clinical demand for same-day or near-real-time pathogen detection, stricter contamination control requirements in regulated manufacturing, and growing emphasis on resilient public health surveillance.

One of the most important shifts is the movement from broad microbial detection to actionable microbial intelligence. Laboratories are no longer focused solely on confirming the presence or absence of microorganisms; they increasingly require strain-level identification, antimicrobial resistance profiling, virulence marker detection, and contamination source tracking. Molecular diagnostics and sequencing-based workflows are supporting this transition by enabling deeper microbial characterization and faster epidemiological insights.

Automation is also changing laboratory economics and quality systems. Automated sample handling, incubated imaging, digital colony counting, robotic liquid handling, and integrated data management reduce manual variability and improve traceability. These capabilities are especially relevant in high-throughput clinical microbiology laboratories, pharmaceutical quality control laboratories, and food testing networks where reproducibility, turnaround time, and audit readiness are critical.

Another structural shift is decentralization. Point-of-care and near-patient microbiology testing are expanding in settings such as emergency departments, intensive care units, outpatient clinics, and remote care environments. While central laboratories remain essential for complex testing and confirmatory analysis, decentralized rapid testing improves early triage, infection control, and treatment initiation when supported by quality assurance and connectivity.

The industry is also being shaped by antimicrobial resistance, healthcare-associated infections, global trade in food and medicines, and heightened biosurveillance needs. These pressures are encouraging adoption of rapid testing platforms that can support syndromic testing, multiplex detection, environmental monitoring, and integrated reporting across healthcare, industrial, and public health applications.

Cumulative Impact of Artificial Intelligence on Rapid Microbiology Testing

Artificial intelligence is becoming a cumulative force in rapid microbiology testing by improving pattern recognition, workflow efficiency, quality control, and decision support. Its impact is most visible where large volumes of images, spectra, genomic sequences, antimicrobial susceptibility data, and laboratory metadata must be interpreted quickly and consistently.

In diagnostic microbiology, AI-enabled image analysis can support automated colony recognition, Gram stain interpretation, microscopy review, and growth detection. These applications help reduce repetitive manual review while improving consistency in high-volume laboratories. When paired with automated incubation and digital imaging systems, AI can help detect microbial growth earlier and flag plates or samples requiring expert review.

In molecular and sequencing-based microbiology, AI and machine learning support bioinformatics workflows, pathogen classification, variant detection, resistance gene interpretation, and outbreak cluster analysis. These tools are increasingly important as laboratories generate complex genomic datasets for infection control, foodborne outbreak investigation, and antimicrobial resistance surveillance. AI can also help prioritize clinically relevant findings from multiplex panels and reduce information overload for physicians and laboratorians.

In pharmaceutical, biotechnology, and food safety environments, AI can strengthen contamination risk management by analyzing environmental monitoring trends, deviation patterns, production data, and microbial identification results. Predictive analytics may help quality teams identify recurring contamination sources, optimize sampling plans, and improve preventive controls without replacing validated microbiological methods.

Despite its promise, AI adoption in rapid microbiology testing requires strong governance. Algorithms must be trained on representative datasets, validated for intended use, monitored for performance drift, and integrated into laboratory quality management systems. Human expertise remains essential for result interpretation, clinical correlation, regulatory compliance, and ethical deployment. The most practical value of AI lies in augmenting microbiologists, not replacing them.

Key Regional Insights for Rapid Microbiology Testing

Asia-Pacific is experiencing strong momentum in rapid microbiology testing due to expanding healthcare infrastructure, rising infectious disease surveillance capacity, increasing pharmaceutical manufacturing, and growing food safety oversight. China, India, Japan, South Korea, Australia, and ASEAN economies are investing in laboratory modernization, molecular diagnostics, and public health testing networks. The region's high population density, cross-border mobility, and diverse disease burden reinforce the need for rapid pathogen detection and antimicrobial resistance monitoring.

Europe benefits from harmonized quality expectations, strong regulatory oversight, and established laboratory accreditation frameworks. The region prioritizes antimicrobial resistance surveillance, healthcare-associated infection reduction, food safety compliance, and pharmaceutical quality control. Countries across Western and Northern Europe demonstrate high adoption of automated and molecular microbiology platforms, while Central and Eastern European countries continue to modernize laboratory capacity through public health investment and accreditation-driven quality improvement.

North America remains a highly advanced region for rapid microbiology testing, supported by mature clinical laboratory networks, strong infection prevention programs, advanced molecular diagnostics adoption, and stringent quality requirements in healthcare, pharmaceutical, and food production environments. The United States and Canada emphasize antimicrobial stewardship, hospital-acquired infection control, foodborne pathogen surveillance, and rapid testing integration with electronic health records and laboratory information systems.

Latin America is advancing rapid microbiology testing through improvements in public health laboratories, hospital diagnostics, food export quality systems, and infectious disease surveillance. Brazil and Mexico play important roles because of their large healthcare systems, food and agriculture sectors, and regional manufacturing activities. Adoption is shaped by the need to improve access, reduce diagnostic delays, and strengthen outbreak detection for bacterial, viral, and parasitic diseases.

Africa's rapid microbiology testing landscape is shaped by infectious disease burden, antimicrobial resistance concerns, food safety needs, and efforts to strengthen decentralized diagnostics. Adoption is supported by investments in public health laboratories, tuberculosis and HIV testing infrastructure, outbreak response systems, and regional disease surveillance. However, implementation requires sustainable procurement, workforce training, quality assurance, and reliable supply chains to support long-term testing capacity.

The Middle East is increasing investment in rapid microbiology testing as part of healthcare modernization, hospital expansion, pharmaceutical quality control, and food import safety programs. Gulf economies are particularly focused on high-acuity hospital diagnostics, infection prevention, and advanced laboratory infrastructure. Regional demand is also influenced by mass gatherings, medical tourism, cross-border travel, and the need for rapid infectious disease preparedness.

Key Group Insights for Rapid Microbiology Testing

NATO member countries are relevant to rapid microbiology testing not only through healthcare and public health systems but also through biodefense, force health protection, and emergency preparedness priorities. Rapid pathogen detection, environmental surveillance, and field-deployable testing platforms support readiness for biological threats, outbreak containment, and continuity of operations in civilian and defense health environments.

The G7 demonstrates high levels of diagnostic infrastructure, regulatory maturity, and laboratory automation. Member countries are actively engaged in antimicrobial resistance policy, pandemic preparedness, food safety monitoring, and pharmaceutical quality oversight. Rapid microbiology testing in G7 economies is increasingly linked to digital laboratory networks, genomic surveillance, and evidence-based clinical decision support.

The European Union provides a structured environment for rapid microbiology testing through regulatory harmonization, laboratory accreditation, antimicrobial resistance surveillance, and food safety legislation. EU-level coordination strengthens comparability of laboratory practices and supports cross-border response to outbreaks and resistance threats. The bloc's emphasis on patient safety, environmental monitoring, and pharmaceutical quality creates a strong foundation for validated rapid microbial methods.

BRICS countries collectively represent diverse but strategically important demand for rapid microbiology testing. Brazil, Russia, India, China, and South Africa face varying combinations of infectious disease burden, expanding healthcare access, pharmaceutical production, food security priorities, and antimicrobial resistance challenges. Their large populations and industrial bases make laboratory capacity building, domestic manufacturing resilience, and public health surveillance central to rapid testing adoption.

ASEAN is gaining relevance in rapid microbiology testing as member economies expand hospital infrastructure, pharmaceutical manufacturing, and food export quality systems. The region's tropical disease profile, urbanization, and cross-border trade create demand for rapid microbial detection in clinical care, public health, and food safety. Laboratory modernization in countries such as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines is supporting broader use of molecular and automated microbiology methods.

The GCC is advancing rapid microbiology testing through healthcare transformation programs, investment in tertiary care hospitals, and stronger infection prevention capabilities. High standards for imported food and medicines, combined with expanding domestic manufacturing and medical tourism, are increasing the need for rapid contamination detection, pathogen identification, and quality control. The region's focus on digital health also supports integration of microbiology results into broader health information systems.

Key Country Insights for Rapid Microbiology Testing

The United States is a leading adopter of rapid microbiology testing due to advanced hospital networks, antimicrobial stewardship initiatives, public health surveillance programs, and strict requirements across pharmaceutical and food production. China is rapidly advancing microbiology testing capacity through hospital modernization, molecular diagnostics expansion, infectious disease monitoring, and pharmaceutical manufacturing quality requirements. Germany's strength lies in high-quality laboratory medicine, pharmaceutical manufacturing, and industrial microbiology, while Japan combines advanced laboratory automation, high healthcare standards, and a strong quality control culture.

India's demand is driven by infectious disease burden, antimicrobial resistance, expanding private and public diagnostics, vaccine and pharmaceutical production, and food safety needs. The United Kingdom prioritizes rapid diagnostics for antimicrobial stewardship, sepsis pathways, infection control, and genomic surveillance. France continues to advance rapid testing through public health systems, hospital diagnostics, and food safety oversight, while Canada emphasizes laboratory quality, infection prevention, and access to rapid diagnostics across geographically dispersed populations.

Italy and Spain are expanding automated and molecular microbiology applications in hospitals, regional laboratories, and food safety programs, with emphasis on timely diagnosis, antimicrobial resistance monitoring, and quality compliance. Brazil's rapid microbiology testing adoption is supported by its large healthcare system, infectious disease surveillance needs, and significant food and agriculture sector, while Mexico is strengthening rapid testing in clinical care, food safety, and export-oriented manufacturing.

Australia emphasizes public health surveillance, food safety, antimicrobial resistance monitoring, and regional biosecurity. Russia's rapid microbiology testing environment is influenced by infectious disease surveillance, hospital diagnostics, and domestic laboratory capacity development. South Korea is a technologically advanced environment for rapid microbiology testing, supported by strong hospital systems, diagnostic innovation, infectious disease preparedness, and biopharmaceutical manufacturing.

Across these countries, adoption patterns differ by reimbursement, laboratory infrastructure, regulatory pathways, workforce capacity, and integration with digital health systems, but the common priority is faster, more reliable microbial detection for clinical and industrial decision-making.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated rapid microbiology testing strategies that align with clinical, regulatory, operational, and quality objectives. Technology selection should be based on intended use, organism coverage, limit of detection, turnaround time, workflow fit, sample type compatibility, quality control requirements, and total implementation readiness rather than speed alone.

Organizations should invest in workflow integration by connecting rapid testing platforms with laboratory information systems, electronic health records, manufacturing execution systems, and quality management systems. Seamless data exchange improves traceability, reduces transcription errors, accelerates reporting, and strengthens surveillance. For clinical users, integration with antimicrobial stewardship teams is essential to ensure rapid results translate into optimized therapy and improved patient management.

Laboratories should implement robust validation and verification protocols before adopting new rapid microbial methods. This includes method comparison, inclusivity and exclusivity testing, interference assessment, reproducibility evaluation, staff competency documentation, and ongoing quality monitoring. In regulated pharmaceutical, biotechnology, and food environments, rapid methods should be incorporated into change control, risk assessment, and audit-ready documentation.

Leaders should also build workforce capability. Rapid microbiology testing requires expertise in molecular methods, automation, bioinformatics, quality assurance, contamination control, and data interpretation. Cross-functional training among microbiologists, clinicians, quality teams, infection prevention specialists, and IT professionals improves adoption success.

AI-enabled and automated platforms should be deployed with clear governance. Decision-support tools must be transparent, validated, monitored, and used in conjunction with expert review. Organizations should also strengthen cybersecurity and data privacy protections as microbiology testing becomes increasingly connected.

Finally, industry stakeholders should focus on resilience. Diversified supply chains, standardized consumables, regional testing capacity, and contingency protocols are critical for maintaining rapid microbiology testing continuity during outbreaks, logistics disruptions, or sudden surges in demand.

Research Methodology

This executive summary is developed through a structured research methodology focused on verified, evidence-based interpretation of the rapid microbiology testing landscape. The methodology combines secondary research, regulatory review, technology assessment, and qualitative synthesis to identify major trends, regional dynamics, application areas, and adoption factors without relying on market sizing, market share, or forecasting.

Secondary research includes review of publicly available guidance, standards, and technical resources from recognized health authorities, food safety agencies, pharmacopoeial bodies, laboratory accreditation organizations, and international public health institutions. The analysis considers established scientific literature on rapid microbial detection, antimicrobial resistance, clinical microbiology workflows, pharmaceutical microbiological quality control, foodborne pathogen testing, and environmental monitoring.

Technology assessment examines major categories of rapid microbiology testing, including molecular diagnostics, immunological assays, mass spectrometry, automated culture systems, digital imaging, flow cytometry, sequencing-based methods, biosensors, and ATP-based detection. Each technology is evaluated based on validated use cases, practical workflow implications, turnaround time benefits, data output, quality requirements, and limitations.

Regional and country insights are synthesized by considering healthcare infrastructure, laboratory modernization, infectious disease surveillance priorities, antimicrobial resistance programs, food safety systems, pharmaceutical and biotechnology manufacturing activity, regulatory expectations, and public health preparedness. Group-level analysis considers the policy, economic, and health system characteristics of NATO, G7, the European Union, BRICS, ASEAN, and GCC.

The methodology emphasizes triangulation, consistency, and exclusion of unsupported claims. Insights are presented as qualitative, data-backed observations rather than numerical market estimates. This approach supports decision-makers seeking practical intelligence on rapid microbiology testing adoption, technology direction, and strategic priorities.

Conclusion

Rapid microbiology testing is becoming an essential capability for faster diagnosis, stronger infection control, safer food and pharmaceutical production, and more resilient public health surveillance. The field is progressing from simple acceleration of microbial detection toward integrated systems that combine automation, molecular precision, digital connectivity, and advanced analytics.

Healthcare organizations are using rapid microbiology testing to support timely treatment decisions, antimicrobial stewardship, and outbreak containment. Pharmaceutical and biotechnology manufacturers are applying rapid methods to improve contamination control, environmental monitoring, and product quality assurance. Food and beverage producers are adopting faster microbial detection to strengthen safety programs and protect supply chains. Public health agencies are leveraging rapid and sequencing-based approaches to monitor emerging pathogens and antimicrobial resistance.

Artificial intelligence, laboratory automation, decentralized testing, and genomic surveillance will continue to influence how rapid microbiology testing is implemented. However, sustainable adoption depends on validation, workforce training, interoperability, quality assurance, and regulatory alignment. Organizations that combine speed with scientific rigor and operational integration will be best positioned to convert rapid microbiology testing into measurable improvements in safety, quality, and decision-making.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rapid Microbiology Testing Market, by Offering

  • 7.1. Introduction
  • 7.2. Consumables
    • 7.2.1. Culture Media
    • 7.2.2. Reagents & Kits
    • 7.2.3. Test Strips
  • 7.3. Instruments
    • 7.3.1. Automated Microbial Identification Systems
    • 7.3.2. Flow Cytometry Systems
    • 7.3.3. Microbial Detection Systems
    • 7.3.4. Sample Preparation Instruments
    • 7.3.5. Spectroscopic & Optical Instruments
  • 7.4. Software
    • 7.4.1. Instrument Control Software
    • 7.4.2. Laboratory Information System
    • 7.4.3. Decision Support & Interpretation
  • 7.5. Services
    • 7.5.1. Rapid Microbial Detection & Identification
    • 7.5.2. Installation
    • 7.5.3. Maintenance & Service Contracts

8. Rapid Microbiology Testing Market, by Detection Method

  • 8.1. Introduction
  • 8.2. Growth-Based Rapid Microbiology Testing
    • 8.2.1. ATP Bioluminescence
    • 8.2.2. Impedance & Conductance
    • 8.2.3. CO2 & Metabolic Monitoring
  • 8.3. Viability-Based Rapid Microbiology Testing
    • 8.3.1. Direct Epifluoresecent Filter Technique (DEFT)
    • 8.3.2. Flow Cytometry (Fluorescence)
  • 8.4. Nucleic Acid-Based Rapid Microbiology Testing
    • 8.4.1. Polymerase Chain Reaction (PCR)
    • 8.4.2. Ribotyping/mMolecular Typing
  • 8.5. Cellular Component-Based Rapid Microbiology Testing

9. Rapid Microbiology Testing Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Human Biological Samples
    • 9.2.1. Blood & Blood Culture
    • 9.2.2. Respiratory Samples
    • 9.2.3. Stool & Enteric Samples
    • 9.2.4. Urine
  • 9.3. Pharmaceutical Samples
  • 9.4. Food & Beverage Samples
  • 9.5. Environmental Samples

10. Rapid Microbiology Testing Market, by Application

  • 10.1. Introduction
  • 10.2. Clinical Disease Diagnostics
  • 10.3. Environmental & Water Testing
  • 10.4. Industrial Testing
    • 10.4.1. Cosmetics & Personal Care Products Testing
    • 10.4.2. Food & Beverage Testing
  • 10.5. Pharmaceutical & Biopharmaceutical Manufacturing
  • 10.6. Research & Academia

11. Rapid Microbiology Testing Market, by End User

  • 11.1. Introduction
  • 11.2. Contract Services Providers
  • 11.3. Food & Beverage Companies
  • 11.4. Laboratories & Hospitals
  • 11.5. Pharmaceutical & Biotechnology Companies
  • 11.6. Environmental & Industrial Organizations

12. Rapid Microbiology Testing Market, by Target Pathogen

  • 12.1. Introduction
  • 12.2. Bacteria
  • 12.3. Fungi
  • 12.4. Viruses

13. Rapid Microbiology Testing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Rapid Microbiology Testing Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. ASEAN
  • 14.6. GCC

15. Rapid Microbiology Testing Market, by Country

  • 15.1. United States
  • 15.2. China
  • 15.3. Germany
  • 15.4. Japan
  • 15.5. India
  • 15.6. United Kingdom
  • 15.7. France
  • 15.8. Canada
  • 15.9. Italy
  • 15.10. Brazil
  • 15.11. Mexico
  • 15.12. Australia
  • 15.13. Russia
  • 15.14. South Korea
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. BioMerieux SA
  • 17.2. Becton, Dickinson and Company
  • 17.3. Danaher Corporation
  • 17.4. Thermo Fisher Scientific, Inc.
  • 17.5. Abbott Laboratories
  • 17.6. Merck KGaA
  • 17.7. Charles River Laboratories International, Inc.
  • 17.8. Bruker Corporation
  • 17.9. Sartorius AG
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. NEOGEN Corporation
  • 17.12. Quidel Corporation
  • 17.13. QIAGEN N.V.
  • 17.14. Rapid Micro Biosystems, Inc.
  • 17.15. Hygiena LLC
  • 17.16. Avantor, Inc.
  • 17.17. BTNX Inc.
  • 17.18. Colifast AS
  • 17.19. Don Whitley Scientific Limited
  • 17.20. Eurofins Scientific SE
  • 17.21. Gradientech AB
  • 17.22. Guangdong Huankai Microbial Sci. & Tech. Co., Ltd.
  • 17.23. PerkinElmer, Inc.
  • 17.24. R-Biopharm AG
  • 17.25. Rqmicro AG
  • 17.26. Serosep Ltd.
  • 17.27. SGS SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL RAPID MICROBIOLOGY TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RAPID MICROBIOLOGY TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RAPID MICROBIOLOGY TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RAPID MICROBIOLOGY TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL RAPID MICROBIOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CULTURE MEDIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CULTURE MEDIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TEST STRIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TEST STRIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TEST STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED MICROBIAL IDENTIFICATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED MICROBIAL IDENTIFICATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED MICROBIAL IDENTIFICATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FLOW CYTOMETRY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FLOW CYTOMETRY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FLOW CYTOMETRY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICROBIAL DETECTION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICROBIAL DETECTION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICROBIAL DETECTION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SAMPLE PREPARATION INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SAMPLE PREPARATION INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SAMPLE PREPARATION INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SPECTROSCOPIC & OPTICAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SPECTROSCOPIC & OPTICAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SPECTROSCOPIC & OPTICAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSTRUMENT CONTROL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSTRUMENT CONTROL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSTRUMENT CONTROL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LABORATORY INFORMATION SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LABORATORY INFORMATION SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LABORATORY INFORMATION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DECISION SUPPORT & INTERPRETATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DECISION SUPPORT & INTERPRETATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DECISION SUPPORT & INTERPRETATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RAPID MICROBIAL DETECTION & IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RAPID MICROBIAL DETECTION & IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RAPID MICROBIAL DETECTION & IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSTALLATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSTALLATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSTALLATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MAINTENANCE & SERVICE CONTRACTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MAINTENANCE & SERVICE CONTRACTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MAINTENANCE & SERVICE CONTRACTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ATP BIOLUMINESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATP BIOLUMINESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ATP BIOLUMINESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMPEDANCE & CONDUCTANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMPEDANCE & CONDUCTANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMPEDANCE & CONDUCTANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CO2 & METABOLIC MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CO2 & METABOLIC MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CO2 & METABOLIC MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIRECT EPIFLUORESECENT FILTER TECHNIQUE (DEFT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIRECT EPIFLUORESECENT FILTER TECHNIQUE (DEFT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIRECT EPIFLUORESECENT FILTER TECHNIQUE (DEFT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FLOW CYTOMETRY (FLUORESCENCE) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FLOW CYTOMETRY (FLUORESCENCE) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FLOW CYTOMETRY (FLUORESCENCE) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RIBOTYPING/MMOLECULAR TYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RIBOTYPING/MMOLECULAR TYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RIBOTYPING/MMOLECULAR TYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN BIOLOGICAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN BIOLOGICAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN BIOLOGICAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD & BLOOD CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD & BLOOD CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD & BLOOD CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESPIRATORY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RESPIRATORY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESPIRATORY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL STOOL & ENTERIC SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL STOOL & ENTERIC SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL STOOL & ENTERIC SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL FOOD & BEVERAGE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL FOOD & BEVERAGE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL FOOD & BEVERAGE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENVIRONMENTAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENVIRONMENTAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ENVIRONMENTAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CLINICAL DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CLINICAL DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CLINICAL DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENVIRONMENTAL & WATER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENVIRONMENTAL & WATER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENVIRONMENTAL & WATER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INDUSTRIAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INDUSTRIAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INDUSTRIAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COSMETICS & PERSONAL CARE PRODUCTS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COSMETICS & PERSONAL CARE PRODUCTS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COSMETICS & PERSONAL CARE PRODUCTS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL FOOD & BEVERAGE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL FOOD & BEVERAGE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL FOOD & BEVERAGE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL & BIOPHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL & BIOPHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL & BIOPHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RESEARCH & ACADEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESEARCH & ACADEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RESEARCH & ACADEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CONTRACT SERVICES PROVIDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONTRACT SERVICES PROVIDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACT SERVICES PROVIDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL FOOD & BEVERAGE COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL FOOD & BEVERAGE COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL FOOD & BEVERAGE COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL LABORATORIES & HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL LABORATORIES & HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LABORATORIES & HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENVIRONMENTAL & INDUSTRIAL ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENVIRONMENTAL & INDUSTRIAL ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ENVIRONMENTAL & INDUSTRIAL ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BACTERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BACTERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BACTERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL FUNGI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL FUNGI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL FUNGI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VIRUSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VIRUSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VIRUSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 265. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 266. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 268. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 270. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 271. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 272. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 273. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 275. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 277. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. NATO RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 279. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 281. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 282. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 285. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 286. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 287. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 288. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 289. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 291. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 293. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. G7 RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROWTH-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY VIABILITY-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY HUMAN BIOLOGICAL SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS RAPID MICROBIOLOGY TESTING MARKET SIZE, BY TARGET PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN RAPID MICROBIOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN RAPID MICROBIOLOGY TESTING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN RAPID MICROBIOLOGY TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN RAPID MICROBIOLOGY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032